食管癌微创与开放食管切除术的长期生存比较
这项回顾性多中心研究纳入2012至2019年间在日本两家高容量癌症中心接受胸腔镜或开放食管切除术的1559例连续食管癌患者,经倾向评分匹配后分析313例。匹配后胸腔镜组1年、3年、5年总生存率分别为87.2%、68.6%、61.8%,开放组分别为84.5%、60.5%、52.1%;加权Cox回归显示胸腔镜组生存显著优于开放组(HR 0.74,95%CI 0.582-0.941)。分层分析显示临床III/IV期及病理II/III/IV期胸腔镜组总生存显著更优,而临床I/II期及病理0/I期无显著差异。
要点
- 匹配后胸腔镜组5年总生存率61.8%,开放组52.1%。
- 加权Cox回归显示胸腔镜组生存显著优于开放组(HR 0.74)。
- 临床III/IV期及病理II/III/IV期胸腔镜组总生存显著更优。
核心结论
- 胸腔镜食管切除术显示生存获益,尤其对高度进展期食管癌。
研究设计与样本
- 回顾性多中心研究,纳入2012至2019年日本两家高容量癌症中心1559例连续食管癌患者,行胸腔镜或开放食管切除术,采用倾向评分匹配分析。
主要发现
- 匹配后共313例分析;开放组1年、3年、5年总生存率分别为84.5%、60.5%、52.1%,胸腔镜组分别为87.2%、68.6%、61.8%。
- 加权Cox回归模型显示胸腔镜组生存显著优于开放组(HR 0.74,95%CI 0.582-0.941)。
- 开放组其他原因死亡事件多于胸腔镜组。
- 分层分析显示临床I或II期与病理0或I期亚组间生存无显著差异。
- 临床III或IV期及病理II、III或IV期胸腔镜组总生存显著更优。
关键数值与推荐
- 匹配后胸腔镜组5年总生存率61.8%,开放组52.1%。
- 加权Cox回归HR 0.74(95%CI 0.582-0.941),胸腔镜组生存更优。
临床怎么用
- 对于高度进展期食管癌(临床III/IV期或病理II/III/IV期),胸腔镜食管切除术可能带来生存获益。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thoracoscopic esophagectomy is a less invasive surgical procedure; however, evidence of its effect on long-term survival is limited. We evaluated long-term survival after the procedure in patients with esophageal carcinoma. METHODS: This retrospective multicenter study involved 1559 consecutive patients with esophageal carcinoma who underwent thoracoscopic esophagectomy or open esophagectomy between 2012 and 2019 at 2 Japanese high-volume cancer centers. Propensity score matching analysis was performed to compare short- and long-term outcomes. In addition, stage-specific survival rates were compared between the groups. RESULTS: There were 313 patients who were matched and analyzed. The 1-, 3-, and 5-year overall survival rates were 84.5%, 60.5%, and 52.1%, respectively, in the matched open esophagectomy group; and 87.2%, 68.6%, and 61.8%, respectively, in the matched thoracoscopic esophagectomy group. The weighted Cox regression model showed significantly better survival in the thoracoscopic esophagectomy group than in the open esophagectomy group (hazard ratio, 0.74; 95% CI, 0.582-0.941). Deaths from other causes occurred more frequently in the open esophagectomy group than in the thoracoscopic esophagectomy group. Stratified analysis showed no significant survival differences between clinical stage I or II and pathologic stage 0 or I subgroups. However, the thoracoscopic esophagectomy groups with clinical stage III or IV and pathologic stage II, III, or IV had significantly better overall survival. CONCLUSIONS: This study demonstrated the survival benefits of thoracoscopic esophagectomy, particularly for highly advanced esophageal carcinoma.
引用
- Igaue S, Fujita T, Oguma J, et al. Long-term Survival in Esophageal Cancer: Comparison of Minimally Invasive and Open Esophagectomy. Ann Thorac Surg. 2024. PMID: 39277159. doi:10.1016/j.athoracsur.2024.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。